Clinical trials: Respiratory Tract Infection
Covid19
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
- Trial name
- NCT04604678
- Testing
- Metformin, Naltrexone
- Where
- United States
- Sponsor
- AgelessRx
Covid19, Pneumonia
Anakinra in the Management of COVID-19 Infection
Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health.
- Conditions
- Covid19, Pneumonia, Cytokine Release Syndrome, Corona Virus Infection
- Trial name
- NCT04643678
- Testing
- Anakinra, Standard of Care
- Where
- Qatar
- Volunteers
- 80 people
- Sponsor
- Hamad Medical Corporation
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT01146015
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
COVID-19
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older
- Trial name
- NCT05710289
- Testing
- Immune Responses
- Volunteers
- healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-FR (NCT04407689)
- Testing
- Interleukin-7
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Revimmune
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in children to evaluate the safety and immunogenicity of an split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900991
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, Coronavirus Pneumonia
A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled…
- Trial name
- NCT06860282
- Testing
- Remdesivir, CX2101A
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Heronova Pharmaceuticals
Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB)
Ketek in CAP / AECB in Ambulatory Adult Patients
To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.
- Trial name
- NCT00546676
- Testing
- Telithromycin
- Volunteers
- 174 people
- Sponsor
- Sanofi
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19…
- Trial name
- NCT04480424
- Testing
- GAMUNEX-C, Standard Medical Treatment
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC
SARS-CoV-2
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894590
- Where
- Japan
- Volunteers
- 13,680 people
- Sponsor
- ModernaTX, Inc.
Influenza
Influenza Burden Assessment in the United States, July1997 - up to April 2009
The study will assess the burden of severe influenza outcomes by age, risk status, and influenza subtype, in order to create a profile of the burden of influenza-related morbidity and mortality in United States from July 1997 to…
- Trial name
- NCT01599390
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus
A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections
The purpose of the study is to assess viral kinetics and clinical symptoms kinetics of Respiratory Syncytial Virus (RSV) in pediatric patients hospitalized with RSV confirmed lower respiratory tract infection (LRTI).
- Trial name
- NCT02132923
- Testing
- No intervention
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Janssen R&D Ireland
Upper Respiratory Tract Infections
A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production
A safety study to compare the effect of two different formulations of PrEP-001 nasal powder when dosed in healthy subjects
- Trial name
- NCT03198676
- Testing
- PrEP-001 6.4 mg, PrEP-001 3.2 mg
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Prep Biopharm Limited
Respiratory Tract Infections
Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens
This first-in-man (FIM) phase I study will evaluate the acute safety, tolerability, and acceptability of the investigational RD19 device among 25 healthy volunteers between the age of 18 and 45.
- Trial name
- NCT04557826
- Testing
- RD19
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- EmitBio Inc.
Diphtheria, Tetanus
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
The purpose of this study is to describe the immunogenicity and safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T fully liquid combined hexavalent vaccine (Hexaxim®) administered at 2, 3, and 4 months of age and at 16 to 17 months…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT02428491
- Testing
- Hexaxim®
- Where
- Vietnam
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Bronchitis
A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
This is a Phase 3, randomized, double-blind, active-controlled, parallel-group, multi-center clinical trial to evaluate the efficacy and safety of DW5121 compared to DW51211 and DW51212 in patients with acute bronchitis.
- Trial name
- NCT07093697
- Testing
- DW5121, DW51211, DW51212
- Where
- 8 sites in South Korea
- Volunteers
- 273 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Observation Safety
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
This is an observational post-marketing study conducted in children and adults immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites.
- Trial name
- NCT01985997
- Where
- United States
- Volunteers
- 95,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on vaccine exposures, pregnancy outcomes, and…
- Trial name
- NCT01945424
- Testing
- Quadrivalent Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Coronavirus Disease 2019, Novel Coronavirus Pneumonia
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
This is an open-label, randomized, blank-controlled treatment clinical study. The objective of this study is to investigate the effect of T89 on improving oxygen saturation and clinical symptoms in patients with Coronavirus…
- Trial name
- NCT04285190
- Testing
- T89
- Sponsor
- Tasly Pharmaceuticals, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.